Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
179M
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
41.7M
-
Shares change
-
+438K
-
Total reported value, excl. options
-
$512M
-
Value change
-
+$3.23M
-
Number of buys
-
44
-
Number of sells
-
-11
-
Price
-
$12.30
Significant Holders of Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) as of Q1 2023
78 filings reported holding PRME - Prime Medicine, Inc. - Common Stock, $0.00001 par value as of Q1 2023.
Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.7M shares
of 179M outstanding shares and own 23.35% of the company stock.
Largest 10 shareholders include Alphabet Inc. (13.3M shares), FMR LLC (8.52M shares), Redmile Group, LLC (1.99M shares), ARK Investment Management LLC (1.92M shares), MWG Management Ltd. (1.84M shares), FIL Ltd (1.81M shares), BlackRock Inc. (1.51M shares), BAKER BROS. ADVISORS LP (1.03M shares), Nikko Asset Management Americas, Inc. (999K shares), and Sumitomo Mitsui Trust Holdings, Inc. (998K shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.